105 related articles for article (PubMed ID: 1315837)
1. The specificity of antibodies induced by infection with rhinovirus type 2.
Carey BS; Barclay WS; Russell SM; Tyrrell DA
J Med Virol; 1992 Apr; 36(4):251-8. PubMed ID: 1315837
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an enzyme-linked immunosorbent assay that measures rhinovirus-specific antibodies in human sera and nasal secretions.
Barclay WS; Callow KA; Sergeant M; al-Nakib W
J Med Virol; 1988 Aug; 25(4):475-82. PubMed ID: 2844987
[TBL] [Abstract][Full Text] [Related]
3. The time course of the humoral immune response to rhinovirus infection.
Barclay WS; al-Nakib W; Higgins PG; Tyrrell DA
Epidemiol Infect; 1989 Dec; 103(3):659-69. PubMed ID: 2558033
[TBL] [Abstract][Full Text] [Related]
4. An ELISA for the detection of rhinovirus specific antibody in serum and nasal secretion.
Barclay WS; Al-Nakib W
J Virol Methods; 1987 Jan; 15(1):53-64. PubMed ID: 3027117
[TBL] [Abstract][Full Text] [Related]
5. A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro.
Behzadi MA; Choi A; Duehr J; Feyznezhad R; Upadhyay C; Schotsaert M; Palese P; Nachbagauer R
Sci Rep; 2020 Jun; 10(1):9750. PubMed ID: 32546721
[TBL] [Abstract][Full Text] [Related]
6. Misdirected antibody responses against an N-terminal epitope on human rhinovirus VP1 as explanation for recurrent RV infections.
Niespodziana K; Napora K; Cabauatan C; Focke-Tejkl M; Keller W; Niederberger V; Tsolia M; Christodoulou I; Papadopoulos NG; Valenta R
FASEB J; 2012 Mar; 26(3):1001-8. PubMed ID: 22121050
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial.
Turner RB; Wecker MT; Pohl G; Witek TJ; McNally E; St George R; Winther B; Hayden FG
JAMA; 1999 May; 281(19):1797-804. PubMed ID: 10340366
[TBL] [Abstract][Full Text] [Related]
8. Characterization of monoclonal antibodies raised against a synthetic peptide capable of inducing a neutralizing response to human rhinovirus type 2.
Barnett PV; Rowlands DJ; Parry NR
J Gen Virol; 1993 Jul; 74 ( Pt 7)():1295-302. PubMed ID: 8393073
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a new enzyme-linked immunosorbent assay (ELISA) in the diagnosis of rhinovirus infection.
al-Nakib W; Dearden CJ; Tyrrell DA
J Med Virol; 1989 Dec; 29(4):268-72. PubMed ID: 2559953
[TBL] [Abstract][Full Text] [Related]
10. Antibody to the nonstructural protein NS1 of Japanese encephalitis virus: potential application of mAb-based indirect ELISA to differentiate infection from vaccination.
Shu PY; Chen LK; Chang SF; Yueh YY; Chow L; Chien LJ; Chin C; Lin TH; Huang JH
Vaccine; 2001 Feb; 19(13-14):1753-63. PubMed ID: 11166901
[TBL] [Abstract][Full Text] [Related]
11. Hemagglutination-inhibition test in rhinovirus infections of volunteers.
Reed SE; Hall TS
Infect Immun; 1973 Jul; 8(1):1-3. PubMed ID: 4352454
[TBL] [Abstract][Full Text] [Related]
12. Versatile carboxyl-terminus of capsid protein of porcine circovirus type 2 were recognized by monoclonal antibodies with pluripotency of binding.
Hung LC; Cheng IC
Mol Immunol; 2017 May; 85():100-110. PubMed ID: 28219820
[TBL] [Abstract][Full Text] [Related]
13. Experimental rhinovirus infection in human volunteers exposed to ozone.
Henderson FW; Dubovi EJ; Harder S; Seal E; Graham D
Am Rev Respir Dis; 1988 May; 137(5):1124-8. PubMed ID: 2461669
[TBL] [Abstract][Full Text] [Related]
14. Immunodominant T-Cell Epitopes in the VP1 Capsid Protein of Rhinovirus Species A and C.
Gaido CM; Stone S; Chopra A; Thomas WR; Le Souëf PN; Hales BJ
J Virol; 2016 Dec; 90(23):10459-10471. PubMed ID: 27630239
[TBL] [Abstract][Full Text] [Related]
15. Generation and diagnostic application of monoclonal antibodies against Seneca Valley virus.
Yang M; van Bruggen R; Xu W
J Vet Diagn Invest; 2012 Jan; 24(1):42-50. PubMed ID: 22362934
[TBL] [Abstract][Full Text] [Related]
16. Detection of rhinovirus RNA in nasal epithelial cells by in situ hybridization.
Bruce C; Chadwick P; al-Nakib W
J Virol Methods; 1990 Oct; 30(1):115-25. PubMed ID: 1964938
[TBL] [Abstract][Full Text] [Related]
17. The nature and spatial distribution of amino acid substitutions conferring resistance to neutralizing monoclonal antibodies in human rhinovirus type 2.
Speller SA; Sangar DV; Clarke BE; Rowlands DJ
J Gen Virol; 1993 Feb; 74 ( Pt 2)():193-200. PubMed ID: 8381460
[TBL] [Abstract][Full Text] [Related]
18. Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1.
Huguenel ED; Cohn D; Dockum DP; Greve JM; Fournel MA; Hammond L; Irwin R; Mahoney J; McClelland A; Muchmore E; Ohlin AC; Scuderi P
Am J Respir Crit Care Med; 1997 Apr; 155(4):1206-10. PubMed ID: 9105055
[TBL] [Abstract][Full Text] [Related]
19. Rhinovirus-induced VP1-specific Antibodies are Group-specific and Associated With Severity of Respiratory Symptoms.
Niespodziana K; Cabauatan CR; Jackson DJ; Gallerano D; Trujillo-Torralbo B; Del Rosario A; Mallia P; Valenta R; Johnston SL
EBioMedicine; 2015 Jan; 2(1):64-70. PubMed ID: 26137535
[TBL] [Abstract][Full Text] [Related]
20. Antibody to rhinovirus in human sera. II. Heterotypic responses.
Fleet WF; Douglas RG; Cate TR; Couch RB
Proc Soc Exp Biol Med; 1968 Feb; 127(2):503-9. PubMed ID: 4296291
[No Abstract] [Full Text] [Related]
[Next] [New Search]
